<i>Astragalus</i>polysaccharide attenuates rat experimental colitis by inducing regulatory T cells in intestinal Peyer’s patches

Zhao, Hai-Mei; Wang, Yan; Huang, Xiaoying; Huang, Min-Fang; Xu, Rong; Yue, Hai-Yang; Zhou, Baosen; Huang, Hongyan; Qi-meng, Sun; Liu, Duan-Yong

doi:10.3748/wjg.v22.i11.3175

Cited by 42 publications

(27 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AM and its active components have been proved to be effective in the treatment of a variety of diseases, such as diabetes mellitus [ 30 ] and cardiovascular disorders [ 31 ]. In recent years, astragal’s polysaccharides effectively reduced the mucosal damage of experimental colitis in mice by shortening colonic length, reducing colon weight index, and reducing macroscopically and histological scores [ 32 ], which is similar to the results of this experiment.…”

Section: Discussionsupporting

confidence: 82%

Astragalus membranaceus (Fisch.) Bunge repairs intestinal mucosal injury induced by LPS in mice

Cui¹,

Wang²,

Sun³

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundAstragalus membranaceus (Fisch.) Bunge is one of the most widely used traditional Chinese herbal medicines. It is used as immune stimulant, tonic, antioxidant, hepatoprotectant, diuretic, antidiabetic, anticancer, and expectorant. The purpose of the study was to investigate the curative effects of the decoction obtained from Astragalus membranaceus root in intestinal mucosal injury induced by LPS in mice. An LPS-induced intestinal mucosal injury mice model was applied in the study.MethodsThe mice were post-treated with Astragalus membranaceus decoction (AMD) for 4 days after 3 days LPS induction. ELISA kit was used to detect the content of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4,IL-6 and IL-8 in the serum of each group mice. The morphological changes in intestinal mucosa at the end of the experiments were observed. Both VH (villus height) and CD (crypt depth) were measured using H&E-stained sections.ResultsThere were significant differences in IL-1β, IL-4,IL-6, IL-8 and TNF-α levels in AMD-treated group on the 7th day compared to the controls group. The VH was lower in duodenum, jejunum and the ileum in LPS-treated mice compared to the control animals. Similarly, there was also decrease in V/C. Compared to the control mice, for AMD-treated mice, VH and CD had no significantly differences.ConclusionsAstragalus membranaceus reduced intestinal mucosal damage and promoted tissue repair by inhibiting the expression of inflammatory cytokine.

show abstract

Section: Discussionsupporting

confidence: 82%

Astragalus membranaceus (Fisch.) Bunge repairs intestinal mucosal injury induced by LPS in mice

Cui¹,

Wang²,

Sun³

et al. 2018

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…It is possible that Astragalus membranaceus contains other components, such as Astragalus polysaccharide that may be mediated by enhancement of CD4 + CD25 + Foxp3 + Tregs. In line with this, Astragalus polysaccharide was demonstrated to possess functions of inducing regulatory T cells [ 31 ]. Moreover, the effects of AS-IV and Astragalus membranaceus may be different when used in different dosage.…”

Section: Discussionmentioning

confidence: 93%

Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway

Jin

Wang

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Astragaloside IV (AS-IV), a main active constituent of Astragalus membranaceus, has been confirmed to have antiasthmatic effects. However, it remained unclear whether the beneficial effects of AS-IV on asthma were attributed to the mTOR inhibition; this issue was the focus of the present work. BALB/c mice were sensitized and challenged with ovalbumin followed with 3 weeks of rest/recovery and then reexposure to ovalbumin. AS-IV was administrated during the time of rest and reexposure. The characteristic features of allergic asthma, including airway hyperreactivity, histopathology, cytokines (IL-4, IL-5, IL-13, IL-17, and INF-γ), and CD4+CD25+Foxp3+Treg cells in bronchoalveolar lavage fluid (BALF), and downstream proteins of mTORC1/2 signaling were examined. AS-IV markedly suppressed airway hyperresponsiveness and reduced IL-4, IL-5, and IL-17 levels and increased INF-γ levels in the BALF. Histological studies showed that AS-IV markedly decreased inflammatory infiltration in the lung tissues. Notably, AS-IV inhibited mTORC1 activity, whereas it had limited effects on mTORC2, as assessed by phosphorylation of mTORC1 and mTORC2 substrates S6 ribosomal protein, p70 S6 Kinase, and Akt, respectively. CD4+CD25+Foxp3+Treg cells in BALF were not significantly changed by AS-IV. Together, these results suggest that the antiasthmatic effects of AS-IV were at least partially from inhibiting the mTORC1 signaling pathway.

show abstract

“…Astragalus is a traditional Chinese medicine that has been studied in depth and widely used in clinics for treatment of diseases, such as hepatitis, 3 diabetes, cancer, 4 and others. 5 Astragalus polysaccharides (APSs) are one of the most important natural active materials extracted from astragalus and are remarkably effective in traditional medicine due to their multitargeting biological activities, including antioxidant, 6 anti-inflammatory, 7 anti-hepatitis B virus (HBV), 3 and immune regulation 5 effects.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice

et al. 2017

View full text Add to dashboard Cite

The purpose of this study was to investigate the effect of astragalus polysaccharides (APSs), active constituents of astragalus, in the treatment of hepatocellular carcinoma (HCC) and their potential as a promising candidate for future anticancer drug development. Astragalus polysaccharide was administered at different doses to HCC H22-bearing mice to investigate their antitumor effects. Results revealed that APS inhibited the growth of H22 cells with a tumor inhibition rate in the APS 400 mg·kg−1 group of 59.01%. Astragalus polysaccharides significantly increased the spleen and thymus indexes, and also the interleukin (IL) 2, IL-6, and tumor necrosis factor α cytokine concentration in serum, indicating that APS influences immune-regulating properties involved in antitumor activity. In addition, APS increased Bax protein expression and decreased Bcl-2 protein expression; these proteins are apoptosis-regulating factors responsible for cell death or survival. Further development and exploration of APS may enable it to become an effective clinical agent for liver cancer therapy.

show abstract

Astragaluspolysaccharide attenuates rat experimental colitis by inducing regulatory T cells in intestinal Peyer’s patches

Abstract: APS effectively ameliorates TNBS-induced experimental colitis in rats, probably through restoring the number of Treg cells, and inhibiting IL-17 levels in Peyer's patches.

Cited by 42 publications

References 52 publications

Astragalus membranaceus (Fisch.) Bunge repairs intestinal mucosal injury induced by LPS in mice

Astragalus membranaceus (Fisch.) Bunge repairs intestinal mucosal injury induced by LPS in mice

Astragaloside IV Ameliorates Airway Inflammation in an Established Murine Model of Asthma by Inhibiting the mTORC1 Signaling Pathway

Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice

Contact Info

Product

Resources

About